InCarda Therapeutics
2 known investors
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
BiotechDigital HealthMedical Devices
Investors · 2
In the news
- InCarda Therapeutics - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- InCarda raises $30M to reimagine afib treatment with drug-device combo | Fierce Biotechfiercebiotech.com · 2020
- InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financingglobenewswire.com · 2020
- InCarda Therapeutics raises $35 million - MassDevicemassdevice.com · 2019
- InCarda Therapeutics Raises over $5M in Series A Financing - FinSMEsfinsmes.com · 2015
- InCarda Raises $5M Series A | PitchBookpitchbook.com